{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:17:10Z","timestamp":1773901030016,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T00:00:00Z","timestamp":1772928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02116-4","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T09:52:00Z","timestamp":1772963520000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world single-center analysis of efficacy and safety in newly diagnosed marginal zone lymphoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Xin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingshu","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningning","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,8]]},"reference":[{"issue":"10","key":"2116_CR1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/ajh.27058","volume":"98","author":"CY Cheah","year":"2023","unstructured":"Cheah CY, Seymour JF, Marginal Zone L. 2023 Update on Diagnosis and Management. Am J Hematol. 2023;98(10):1645\u201357.","journal-title":"Am J Hematol"},{"key":"2116_CR2","unstructured":"Alderuccio JP, Kahl BS. Current Treatments in Marginal Zone Lymphoma. Oncology (Williston Park, N.Y.), 2022, 36(4): 206\u201315."},{"issue":"7","key":"2116_CR3","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36(7):1720\u201348.","journal-title":"Leukemia"},{"issue":"6","key":"2116_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1056\/NEJMra2102568","volume":"386","author":"D Rossi","year":"2022","unstructured":"Rossi D, Bertoni F, Zucca E. Marginal-Zone Lymphomas. N Engl J Med. 2022;386(6):568\u201381.","journal-title":"N Engl J Med"},{"issue":"1","key":"2116_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","volume":"31","author":"E Zucca","year":"2020","unstructured":"Zucca E, Arcaini L, Buske C, et al. Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(1):17\u201329.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"1","key":"2116_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/bjh.12730","volume":"165","author":"MO Khalil","year":"2014","unstructured":"Khalil MO, Morton LM, Devesa SS, et al. Incidence of Marginal Zone Lymphoma in the United States, 2001\u20132009 with a Focus on Primary Anatomic Site. Br J Haematol. 2014;165(1):67\u201377.","journal-title":"Br J Haematol"},{"issue":"3","key":"2116_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3892\/ol.2023.13994","volume":"26","author":"V Fiorentino","year":"2023","unstructured":"Fiorentino V, Pizzimenti C, Pierconti F, et al. Unusual Localization and Clinical Presentation of Primary Central Nervous System Extranodal Marginal Zone B\u2013cell Lymphoma: A Case Report. Oncol Lett. 2023;26(3):408.","journal-title":"Oncol Lett"},{"issue":"7","key":"2116_CR8","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.3390\/cancers14071742","volume":"14","author":"A Di Rocco","year":"2022","unstructured":"Di Rocco A, Petrucci L, Assanto GM, et al. Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. Cancers. 2022;14(7):1742.","journal-title":"Cancers"},{"issue":"1","key":"2116_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3324\/haematol.2021.278755","volume":"107","author":"CY Cheah","year":"2022","unstructured":"Cheah CY, Zucca E, Rossi D, et al. Marginal Zone Lymphoma: Present Status and Future Perspectives. Haematologica. 2022;107(1):35\u201343.","journal-title":"Haematologica"},{"issue":"12","key":"2116_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11864-019-0687-5","volume":"20","author":"A Sindel","year":"2019","unstructured":"Sindel A, Al-Juhaishi T, Yazbeck V. Marginal Zone Lymphoma: State-of-the-Art Treatment. Curr Treat Options Oncol. 2019;20(12):90.","journal-title":"Curr Treat Options Oncol"},{"issue":"17","key":"2116_CR11","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","volume":"35","author":"E Zucca","year":"2017","unstructured":"Zucca E, Conconi A, Martinelli G, et al. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncology: Official J Am Soc Clin Oncol. 2017;35(17):1905\u201312.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"3","key":"2116_CR12","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","volume":"6","author":"M Herold","year":"2022","unstructured":"Herold M, Hoster E, Janssens A, et al. Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial. HemaSphere. 2022;6(3):e699.","journal-title":"HemaSphere"},{"issue":"1","key":"2116_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/mabs.22771","volume":"5","author":"C Klein","year":"2013","unstructured":"Klein C, Lammens A, Sch\u00e4fer W, et al. Epitope Interactions of Monoclonal Antibodies Targeting CD20 and Their Relationship to Functional Properties. mAbs. 2013;5(1):22\u201333.","journal-title":"mAbs"},{"issue":"2","key":"2116_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/14712598.2020.1822318","volume":"21","author":"C Klein","year":"2021","unstructured":"Klein C, Jamois C, Nielsen T. Anti-CD20 Treatment for B-Cell Malignancies: Current Status and Future Directions. Expert Opin Biol Ther. 2021;21(2):161\u201381.","journal-title":"Expert Opin Biol Ther"},{"issue":"22","key":"2116_CR15","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, et al. Increasing the Efficacy of CD20 Antibody Therapy through the Engineering of a New Type II Anti-CD20 Antibody with Enhanced Direct and Immune Effector Cell-Mediated B-Cell Cytotoxicity. Blood. 2010;115(22):4393\u2013402.","journal-title":"Blood"},{"issue":"4","key":"2116_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s12254-024-00998-2","volume":"17","author":"M Raderer","year":"2024","unstructured":"Raderer M, Kiesewetter B. Recent Developments in Marginal Zone Lymphoma. memo -. Magazine Eur Med Oncol. 2024;17(4):247\u201350.","journal-title":"Magazine Eur Med Oncol"},{"issue":"Supplement 1","key":"2116_CR17","doi-asserted-by":"publisher","first-page":"5147","DOI":"10.1182\/blood-2023-185182","volume":"142","author":"N Epperla","year":"2023","unstructured":"Epperla N, Annunzio K, Shouse GP, et al. Impact of Maintenance Rituximab Following First-Line Systemic Therapy on Outcomes in Patients with Marginal Zone Lymphoma: Real-World Evidence from 10 US Centers. Blood. 2023;142(Supplement 1):5147.","journal-title":"Blood"},{"issue":"11","key":"2116_CR18","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.3324\/haematol.2019.237990","volume":"105","author":"A Conconi","year":"2020","unstructured":"Conconi A, Thieblemont C, Cascione L, et al. Early Progression of Disease Predicts Shorter Survival in MALT Lymphoma Patients Receiving Systemic Treatment. Haematologica. 2020;105(11):2592\u20137.","journal-title":"Haematologica"},{"issue":"6","key":"2116_CR19","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/ajh.25473","volume":"94","author":"SI Tracy","year":"2019","unstructured":"Tracy SI, Larson MC, Feldman AL, et al. The Utility of Prognostic Indices, Early Events, and Histological Subtypes on Predicting Outcomes in Non-Follicular Indolent B-Cell Lymphomas. Am J Hematol. 2019;94(6):658\u201366.","journal-title":"Am J Hematol"},{"issue":"1","key":"2116_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13045-023-01448-y","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Welkie RL, Torka P, et al. Impact of Early Relapse within 24 Months after First-Line Systemic Therapy (POD24) on Outcomes in Patients with Marginal Zone Lymphoma: A US Multisite Study. J Hematol Oncol. 2023;16(1):49.","journal-title":"J Hematol Oncol"},{"key":"2116_CR21","doi-asserted-by":"publisher","first-page":"863021","DOI":"10.3389\/fonc.2022.863021","volume":"12","author":"F Gao","year":"2022","unstructured":"Gao F, Zhang T, Liu X, et al. Clinical Features and Outcomes of Patients with Follicular Lymphoma: A Real-World Study of 926 Patients in China. Front Oncol. 2022;12:863021.","journal-title":"Front Oncol"},{"issue":"10","key":"2116_CR22","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1182\/blood.2019001088","volume":"134","author":"S Luminari","year":"2019","unstructured":"Luminari S, Merli M, Rattotti S, et al. Early Progression as a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study. Blood. 2019;134(10):798\u2013801.","journal-title":"Blood"},{"issue":"3","key":"2116_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.5045\/br.2017.52.3.200","volume":"52","author":"J Seo","year":"2017","unstructured":"Seo J, Kim WS, Kim JS, et al. Platelet to Lymphocyte Ratio (PLR) Retains Independent Prognostic Significance in Advanced Stage Marginal Zone Lymphoma Patients Treated with Rituximab, Cyclophosphamide, Vincristine, and Prednisone Combination Chemotherapy (R-CVP): Consortium for Improving Survival of Lymphoma Trial. Blood Res. 2017;52(3):200\u20136.","journal-title":"Blood Res"},{"issue":"4","key":"2116_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00277-011-1337-6","volume":"91","author":"HJ Kang","year":"2012","unstructured":"Kang HJ, Kim WS, Kim SJ, et al. Phase II Trial of Rituximab plus CVP Combination Chemotherapy for Advanced Stage Marginal Zone Lymphoma as a First-Line Therapy: Consortium for Improving Survival of Lymphoma (CISL) Study. Ann Hematol. 2012;91(4):543\u201351.","journal-title":"Ann Hematol"},{"issue":"19","key":"2116_CR25","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Van der Jagt R, Kahl BS, et al. Randomized Trial of Bendamustine-Rituximab or R-CHOP\/R-CVP in First-Line Treatment of Indolent NHL or MCL: The BRIGHT Study. Blood. 2014;123(19):2944\u201352.","journal-title":"Blood"},{"issue":"4","key":"2116_CR26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/hon.2773","volume":"38","author":"A Morigi","year":"2020","unstructured":"Morigi A, Argnani L, Lolli G, et al. Bendamustine-Rituximab Regimen in Untreated Indolent Marginal Zone Lymphoma: Experience on 65 Patients. Hematol Oncol. 2020;38(4):487\u201392.","journal-title":"Hematol Oncol"},{"issue":"9873","key":"2116_CR27","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus Rituximab versus CHOP plus Rituximab as First-Line Treatment for Patients with Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised, Phase 3 Non-Inferiority Trial. Lancet (London England). 2013;381(9873):1203\u201310.","journal-title":"Lancet (London England)"},{"issue":"2","key":"2116_CR28","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/curroncol30020135","volume":"30","author":"A Peters","year":"2023","unstructured":"Peters A, Keating MM, Nikonova A, et al. Management of Marginal Zone Lymphoma: A Canadian Perspective. Curr Oncol (Toronto Ont). 2023;30(2):1745\u201359.","journal-title":"Curr Oncol (Toronto Ont)"},{"issue":"12","key":"2116_CR29","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncology: Official J Am Soc Clin Oncol. 2019;37(12):984\u201391.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10","key":"2116_CR30","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00277-022-04919-3","volume":"101","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xu J, Li J, et al. Rituximab plus Cladribine versus R-CHOP in Frontline Management of Marginal Zone Lymphoma in China: A Propensity-Score Matched Multicenter Study. Ann Hematol. 2022;101(10):2139\u201348.","journal-title":"Ann Hematol"},{"key":"2116_CR31","doi-asserted-by":"crossref","unstructured":"Grunenberg A, Kaiser LM, Woelfle S et al. Phase II Trial Evaluating the Efficacy and Safety of the Anti-CD20 Monoclonal Antibody Obinutuzumab in Patients with Marginal Zone Lymphoma. Future Oncology (London, England), 2020, 16(13): 817\u201325.","DOI":"10.2217\/fon-2020-0071"},{"issue":"12","key":"2116_CR32","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1097\/HS9.0000000000000807","volume":"6","author":"D Galusic","year":"2022","unstructured":"Galusic D, Basic-Kinda S, Pijuk A, et al. Efficacy and Safety of Obinutuzumab-Chemotherapy Combinations in Front-Line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. HemaSphere. 2022;6(12):e807.","journal-title":"HemaSphere"},{"issue":"125","key":"2116_CR33","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.6004\/jnccn.2020.5035","volume":"18","author":"SD Smith","year":"2020","unstructured":"Smith SD. Challenges and Opportunities in Marginal Zone Lymphoma: Implications of Biology on Treatment. J Natl Compr Canc Netw. 2020;18(125):1761\u20133.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2116_CR34","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s00432-022-04155-2","volume":"149","author":"G Claustre","year":"2023","unstructured":"Claustre G, Boulanger C, Maloisel F, et al. Comparative Analysis of Rituximab or Obinutuzumab Combined with CHOP in First-Line Treatment of Follicular Lymphoma. J Cancer Res Clin Oncol. 2023;149(5):1883\u201393.","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02116-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02116-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T02:50:20Z","timestamp":1773888620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02116-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2116"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02116-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,8]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving humans were approved by Shandong Provincial Hospital Affiliated to Shandong First Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. The approved title is \u201cReal-World Single-Center Analysis of Efficacy and Safety in Newly Diagnosed Marginal Zone Lymphoma\u201d, with approval number\n                      NSFC: NO.2024-84\n                      and approval date January 1, 2024.Written informed consent for participation in this study was provided by the participants\u2019 legal guardians\/next of kin. Written informed consent was obtained from the minor(s)\u2019legal guardian\/ next of kin for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patients provided written informed consent for publication, authorizing the use of their clinical data for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent for publication"}}],"article-number":"187"}}